Two different CD33/CD16 bsAbs have been shown to efficiently kill acute myeloid leukemia (AML) cells or stem cells from myelodysplastic syndrome, a precursor of AML (155–157). The gene discussed is FCGR3A; the disease is acute myeloid leukemia.